ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
A triplet of Keytruda failures
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
ASH 2023 preview – Darzalex gets a first-line boost from Perseus
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
ASCO Plenary – what Astellas does Keymed might do better
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
